El interés en corto de Bone Biologics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Bone Biologics. Los datos de interés en corto se actualizan cada dos semanas.

Bone Biologics (NASDAQ:BBLG) Bolsa, Informe de interés en corto

Bone Biologics

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Bone Biologics Corp

THCH

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

TSDD

Kevin O'Leary, better known as &#8220;Mr. Wonderful&#8221; on Shark Tank, has built an empire by doing one thing well: listening. Whether it's his investments, business ventures or career advice, O'Leary says tuning into the market – and people – has been his secret weapon.
So what would he do if he weren't in finance? He answered that himself on Facebook: <a href="https://www.facebook.com/watch/?v=2517803078410533">&#8220;What would I be doing? </a>What I&#8217;m always doing: I&#8217;m listening to the market. I&#8217;m a salesperson. I sell stuff.&#8221;
Here's how his strategy could be a game-changer for your wallet.
Don't Miss:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
<h2 class="wp-block-heading">Solving Problems, Selling Solutions</h2>
O'Leary doesn't just invest; he identifies pain points. Problems people are dealing with every day. Then, he finds solutions and sells them. That's the game, he says. It's not rocket science – it's about <a href="https://www.benzinga.com/personal-finance/24/12/42293874/corporate-america-got-lost-with-idiot-management-and-inability-to-read-the-room-says-kevin-oleary-citing-target-and-anheuser-busch">staying in tune</a> with people&#8217;s needs and delivering it.
<h2 class="wp-block-heading">Why Listening Matters</h2>
In the fast-moving world of business and finance, O'Leary believes listening isn't just important – it's critical. "The lesson is: Listen to your gut because that is your experience [talking]," he told CNBC, as reported by Sportskeeda.
But it's not just about intuition. He relies on hard data, too. And the results speak for themselves. "This is real data: 75% of my returns have come from companies run by women," he said.
O'Leary trusts both his instincts and the numbers. It's a balance that could help any investor.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">The Cost Of Risk</h2>
Even with all his success, O'Leary isn't shy about discussing the risks. &#8220;No matter how you feel and how optimistic you are, in the moment of making an investment, you have no idea of the outcome,&#8221; he explained.
The takeaway? Even the best in the business can't predict every move. That's why O'Leary stresses the importance of being realistic and prepared.
<h2 class="wp-block-heading">Truth Hurts, But It Works</h2>
O'Leary is known for his bluntness and he doesn't apologize for it. "Maybe people think I&#8217;m bullying them. That's not true. I'm the only guy there who tells the truth all the time," he told Business Insider.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
And while the truth may sting, it's often the wake-up call entrepreneurs and investors need to succeed.
<h2 class="wp-block-heading">Takeaway For Your Finances</h2>
Listening – whether to the market, the data or your instincts – might just be your most valuable <a href="https://www.benzinga.com/personal-finance/24/01/42768256/to-survive-no-matter-what-kevin-oleary-says-you-need-5m-in-the-bank-you-can-take-care-of-a-lot-of-people">financial skill.</a> Like O'Leary, focus on solving problems, trust the numbers and be brutally honest about risks.
It's not about being perfect. It's about staying sharp, curious and in the game. As O'Leary puts it, <a href="https://www.facebook.com/watch/?v=1529010681077975">&#8220;That's how you win.</a> Always.&#8221;
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

Kevin O'Leary's Market Strategy Revealed – Why Listening Could Be Your Biggest Financial Asset

Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially pivotal advance in addressing this serious health challenge.
Tivoxavir Marboxil, an oral cap-dependent endonuclease inhibitor, targets a highly conserved influenza protein, demonstrating broad-spectrum efficacy against various flu strains, including avian influenza. Preclinical studies have highlighted its potent activity against drug-resistant and highly pathogenic bird flu viruses, both in vitro and in vivo.
In a recent randomized, double-blind, placebo-controlled Phase 1 clinical trial, the safety, tolerability, and pharmacokinetics of single ascending doses of Tivoxavir Marboxil were evaluated in healthy, influenza-negative adult volunteers. The trial reported no treatment-related adverse events. Notably, a single dose maintained plasma drug levels above the effective concentration (EC90) for over 23 days, indicating the potential for sustained efficacy with a one-time administration.

Biotech

News

General

TRAW

Expert Systems Announced Milestone in Traws Pharma's H5N1 Program; Tivoxavir Marboxil Shows Broad-Spectrum Efficacy In Phase 1 Trial With No Adverse Events; Single Dose Maintains Plasma Levels Above EC90 For Over 23 Days

Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>), the video-sharing platform and cloud services provider, today announced that it has entered a cloud services agreement with the Government of El Salvador. The deal represents the increasing migration of the world toward companies that align more with the values of freedom that Rumble represents. Rumble's services to El Salvador will include cloud storage (object and block storage), cloud computing, databases, load balancers, and Kubernetes integration.

Contracts

Global

Rumble Announces Cloud Agreement With Government Of El Salvador

Freight Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) reported quarterly losses of $(15.94) per share. The company reported $8.13 million in sales this quarter. This is a 6.64 percent increase over sales of $7.62 million the same period last year.

Earnings

FRGT

Freight Technologies H1 EPS $(15.94), Sales $8.13M Up From $7.62M YoY

NioCorp Developments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) reported quarterly losses of $(0.01) per share. This is a 88.89 percent increase over losses of $(0.09) per share from the same period last year.

NioCorp Developments Q2 EPS $(0.01) Up From $(0.09) YoY

Associated Capital Group, Inc. ("AC" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>), announced today a preliminary range for its fourth quarter book value of $42.04 to $42.24 per share. These estimates reflect the $2 per share special dividend paid on November 4, 2024 to Class A and Class B shareholders of record on October 21, 2024. This range compares to book value of $42.02 per share at September 30, 2024.
AC will be issuing further details on its financial results in February.

Guidance

Associated Capital Preliminary Range For Q4 Book Value Of $42.04-$42.24 Per Share

<a href="https://www.globenewswire.com/Tracker?data=qb1HHh-7BoDr3e2cTK3XuK5vOFdoebS8Qhb97jUgV0sIMhaXcUKCtORUq7DN5LgVqGFqt8LBrT73W53GxsdTWdUgCCb8jr8YMeG-hI3w_Ug=">Matinas BioPharma</a> Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.
The Company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the NYSE American Company Guide.

MTNB

Matinas BioPharma Receives NYSE Noncompliance Notice

<a href="https://www.globenewswire.com/Tracker?data=r1yLSj8-eYfdDk9miH1wyKIvR1AyJ-FnW23L4uaeNPkpYB1cuJw4HLQgOHUr8cMIDUKl1u5biCqQnc_jg0mT5jgnm_5u0Bi7IEjyIFJCWXobEifXrzscWFQlQs8wFUSa">Photronics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAB#NASDAQ">PLAB</a>), a worldwide leader in photomask technologies and solutions, announced today the appointment of George Macricostas to the position of Executive Chairman, effective January 6, 2025.
Mr. Macricostas has over 30 years of technical and management experience in business operations and information technology. He has been a member of the Photronics Board of Directors since 2002, serving on the Nomination and Cybersecurity committees, and most recently as Chairman of the Compensation Committee. With his transition to the Executive Chairman role, Mr. Macricostas will be succeeded in his committee assignments by Mr. David Garcia, who became a member of the Board of Directors in December 2024. As a result of the appointment, both George Macricostas and Constantine ("Deno") Macricostas will no longer be considered independent directors, resulting in a Board of Directors of nine, six of whom are independent.

Management

PLAB

Photronics Appoints George Macricostas To The Position Of Executive Chairman, Effective January 6, 2025.

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) (the "Company," "we," "us," and "our") today announced preliminary results for the third quarter of fiscal year 2025 ended December 28, 2024 in advance of its participation in the ICR Conference on Monday, January 13, 2025. A Supplemental Financial Presentation is available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.bootbarn.com&amp;esheet=54176560&amp;newsitemid=20250110378200&amp;lan=en-US&amp;anchor=investor.bootbarn.com&amp;index=1&amp;md5=3f2f63b900cfec04282786d246c56c7a">investor.bootbarn.com</a>.
Preliminary Results for the Third Quarter of Fiscal Year 2025
For the third quarter ended December 28, 2024, the Company expects to report:
<ul>
<li>Net sales of approximately $608.2 million, representing growth of 16.9% over the prior year.</li>
<li>Same store sales growth of approximately 8.6%, with retail store same store sales growth of approximately 8.2% and e-commerce same store sales growth of approximately 11.1%.</li>
<li>Income from operations of approximately $99.5 million compared to $75.1 million in the prior-year period. Included in income from operations is a net benefit of $6.7 million related to the Chief Executive Officer ("CEO") transition. This benefit primarily relates to the forfeiture of unvested long-term equity incentive compensation and reversal of fiscal 2025 cash incentive bonus expense for the Company's former CEO. These expenses were not deductible for income taxes.</li>
<li>Net income per diluted share of approximately $2.43 based on 30.9 million weighted average diluted shares outstanding and a 24.3% effective tax rate, compared to net income per diluted share of $1.81 in the prior-year period. Included in net income per diluted share is an estimated $0.22 benefit related to the CEO transition.</li>
<li>The Company opened 13 new stores in the third quarter, or 39 stores year-to-date, bringing its total store count to 438.</li>
</ul>

BOOT

Boot Barn Preliminary Q3 Revenue Of ~$608.2M, Up 16.9% YoY; Same Store Sales Growth Of ~8.6%; Retail Store Same Store Sales Growth Of ~8.2%; e-Commerce Same Store Sales Growth Of ~11.1%; EPS Of ~$2.43

SMX (Security Matters) PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>, SMXWW))) announces that on January 7, 2025, it received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC due to the Company's non-compliance with Nasdaq Listing Rules 5620(a), as the Company did not hold an annual general meeting of shareholders within twelve months of the end of the Company's fiscal year ended December 31, 2023.
The Company intends to hold an annual general meeting of stockholders in February 2025, during which the Company will put before the shareholders for approval all matters that would have been tabled at the annual general meeting held during the calendar year 2024 (had it been so held).

SMX Receives Nasdaq Listing Deficiency Notice

13 analysts have expressed a variety of opinions on Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.71, a high estimate of $12.00, and a low estimate of $4.00. This current average represents a 31.95% decrease from the previous average price target of $11.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736546481_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Sunnova Energy Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jeff Osborne</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.25</td>
<td>$9.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sunnova Energy Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sunnova Energy Intl compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Sunnova Energy Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NOVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sunnova Energy Intl analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Sunnova Energy Intl: A Closer Look</h2>
Sunnova Energy International Inc is a residential solar and energy storage service provider company. It offers services such as operations and maintenance, monitoring, repairs and replacements, equipment upgrades, and onsite power optimization. The products and services offered by the group include Add-on battery storage, Home solar protection plans, New solar battery storage, and various other solar systems. It operates in a single reportable segment: solar energy products and services.
<h3>A Deep Dive into Sunnova Energy Intl's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Sunnova Energy Intl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.6% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Sunnova Energy Intl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -52.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sunnova Energy Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 4.63, Sunnova Energy Intl faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NOVA

The Analyst Verdict: Sunnova Energy Intl In The Eyes Of 13 Experts

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $94.85, a high estimate of $120.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 14.49%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736546473_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Skyworks Solutions. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$84.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$72.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Stoss</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$80.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Peter Peng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$87.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skyworks Solutions. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Skyworks Solutions compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Skyworks Solutions's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Skyworks Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SWKS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Skyworks Solutions analyst ratings.</a>
<h2>About Skyworks Solutions</h2>
Skyworks Solutions Inc produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
<h3>Unraveling the Financial Story of Skyworks Solutions</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Skyworks Solutions's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.9%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Skyworks Solutions's net margin is impressive, surpassing industry averages. With a net margin of 5.9%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Skyworks Solutions's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.95%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.73%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Skyworks Solutions's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SWKS

Forecasting The Future: 13 Analyst Projections For Skyworks Solutions

PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated PBF Energy and provided 12-month price targets. The average target is $31.09, accompanied by a high estimate of $36.00 and a low estimate of $20.00. Experiencing a 11.17% decline, the current average is now lower than the previous average price target of $35.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736546463_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of PBF Energy's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Royall</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gabelman</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Randy Ollenberger</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$34.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gabelman</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$27.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PBF Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of PBF Energy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of PBF Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into PBF Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PBF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PBF Energy analyst ratings.</a>
<h2>All You Need to Know About PBF Energy</h2>
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines and storage facilities. The Logistics segment consists solely of PBFX's operations.
<h3>Unraveling the Financial Story of PBF Energy</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: PBF Energy's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -21.91%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: PBF Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.41% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PBF Energy's ROE excels beyond industry benchmarks, reaching -4.71%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): PBF Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: PBF Energy's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into PBF Energy Stock: Analyst Perspectives (11 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Westlake, presenting an average target of $151.75, a high estimate of $167.00, and a low estimate of $135.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.38%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736546455_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Westlake. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Maintains</td>
<td>Buy</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$165.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Joshua Raskin</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$144.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$151.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Westlake. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Westlake compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Westlake's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Westlake's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WLK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Westlake analyst ratings.</a>
<h2>Delving into Westlake's Background</h2>
Westlake Corp is a manufacturer and supplier of chemicals, polymers and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
<h3>Key Indicators: Westlake's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Westlake's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 0.06%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Westlake's net margin is impressive, surpassing industry averages. With a net margin of 3.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Westlake's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.51%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Westlake adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Westlake In The Eyes Of 8 Experts

Across the recent three months, 10 analysts have shared their insights on Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.1, a high estimate of $70.00, and a low estimate of $51.00. Witnessing a positive shift, the current average has risen by 18.4% from the previous average price target of $47.38.
<img src="https://www.benzinga.com/files/images/story/2025/1736546433_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Williams Companies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Holly Stewart</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Shneur Gershuni</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$52.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Robert Catellier</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Williams Companies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Williams Companies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Williams Companies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Williams Companies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WMB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Williams Companies analyst ratings.</a>
<h2>Get to Know Williams Companies Better</h2>
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
<h3>Williams Companies's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Williams Companies's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.67%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Williams Companies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Williams Companies's ROE stands out, surpassing industry averages. With an impressive ROE of 5.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Williams Companies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.33%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.19, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Williams Companies Stock

In the last three months, 8 analysts have published ratings on Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $156.0, a high estimate of $196.00, and a low estimate of $134.00. A 1.5% drop is evident in the current average compared to the previous average price target of $158.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1736546424_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Mohawk Industries among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$141.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$134.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Overweight</td>
<td>$196.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Mohawk Industries. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Mohawk Industries compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Mohawk Industries's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Mohawk Industries's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MHK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Mohawk Industries analyst ratings.</a>
<h2>All You Need to Know About Mohawk Industries</h2>
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States.
<h3>Key Indicators: Mohawk Industries's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Mohawk Industries's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -1.7% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Mohawk Industries's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.96% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Mohawk Industries's ROA excels beyond industry benchmarks, reaching 1.22%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.33.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Mohawk Industries Stock: Analyst Perspectives (8 Ratings)

Offerings

BTAI

BioXcel Therapeutics Files For Resale Of Up To 5.1M Shares By The Selling Stockholders

GrafTech International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) ("GrafTech" or the "Company") today announced that it has entered into a cooperation agreement (the "Cooperation Agreement") with one of the Company's largest stockholders, Mr. Nilesh Undavia, who owns approximately 6.7% of the Company's outstanding common stock.
Pursuant to the Cooperation Agreement, GrafTech has appointed Sachin Shivaram to the Board of Directors of the Company (the "Board"), effective immediately. Additionally, GrafTech and Mr. Undavia will work together to identify a mutually agreed upon independent candidate to nominate for election to the Board at the 2025 annual meeting of stockholders of the Company (the "2025 Annual Meeting"), although if the parties are unable to find a mutually agreeable candidate in time for inclusion on the ballot of the 2025 Annual Meeting, they will continue to work together to find a mutually agreeable candidate to be appointed as a director on the Board.

GrafTech Enters Cooperation Agreement With Stakeholder Nilesh Undavia, Owning 6.7%, Appoints Sachin Shivaram To Board, Seeks Independent Candidate For 2025 Board Election

Bone Biologics Corp (BBLG) stock has risen 2.99% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Bone Biologics Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BBLG!See Full BBLG ReportWhat is Stock Sentiment?Sentiment is a

Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Up 2.99% in a Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the first quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -$1.31. This was above the analyst estimate for EPS of -$7.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bblg-stock-earnings-bone-biologics-for-q1-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024

Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest ones worth watching on Wednesday morning!



Moving stocks are new deals and contracts, earnings reports, stock offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is rocketing more than 821% on a deal to <a href="https://www.nasdaq.com/press-release/actelis-receives-new-orders-supply-three-military-bases-cyber-hardened-networking">supply technology to three military bases</a>.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are soaring over 139% with heavy trading roughly <a href="https://www.marketwatch.com/story/mf-international-shares-more-than-double-in-trading-debut-after-ipo-607bbac5">one month after its public debut</a>.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging more than 63% after falling yesterday on an <a href="https://www.investing.com/news/company-news/endra-life-sciences-sets-8-million-stock-offering-93CH-3470094">$8 million stock offering</a>.</li>



<li>WalkMe (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkme-stock-quote/">WKME</a>) shares are gaining over 43% on a <a href="https://seekingalpha.com/news/4112995-walkme-stock-leaps-after-15b-takeover-deal-with-sap?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">$1.5 billion takeover deal</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is rising more than 33% with strong early morning trading.</li>



<li>Moving iMage Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mitq-stock-quote/">MITQ</a>) shares are increasing over 25% after being <a href="https://www.nasdaq.com/press-release/moving-image-technologies-mit-awarded-multi-million-dollar-contract-state-art-alamo">granted a new contract</a>.</li>



<li>Jayud Global Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/jyd-stock-quote/">JYD</a>) stock is heading more than 22% higher alongside heavy trading this morning.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are climbing over 20% <a href="https://www.nasdaq.com/press-release/uotta-technology-be-adopted-portuguese-national-taxi-association-drive">on a deal</a> with the Portuguese National Taxi Association.</li>



<li>Stitch Fix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfix-stock-quote/">SFIX</a>) stock is jumping more than 16% after <a href="https://finance.yahoo.com/news/stitch-fix-sfix-reports-q3-212003374.html">beating revenue estimates in fiscal Q3</a>.</li>



<li>Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) shares are up over 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318374243&amp;type=PDF&amp;symbol=CLDI&amp;cdn=26f24d99b28a708fa7751a113b343d34&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-04">warrant exercise agreement</a>.</li>
</ol><h2>10 Top Losers</h2><ol></ol><ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is retreating more than 26% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">following a rally yesterday</a>.</li>



<li>SilverSun Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/ssnt-stock-quote/">SSNT</a>) shares are diving close to 23% on <a href="https://ca.finance.yahoo.com/news/insider-sale-ceo-mark-meller-070316512.html">a CEO stock sale</a>.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) stock is pulling back over 21% <a href="https://investorplace.com/2024/06/why-is-sobr-safe-sobr-stock-up-83-today/">after yesterday&rsquo;s rally</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares are tumbling more than 18% without any clear news this morning.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/06/why-is-fresh2-group-fres-stock-up-31-today/">after climbing higher yesterday</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are sliding more than 14% despite a lack of news today.</li>



<li>Vast Renewables (NASDAQ:<a href="https://investorplace.com/stock-quotes/vste-stock-quote/">VSTE</a>) stock is dropping over 14% today.</li>



<li>ThredUp (NASDAQ:<a href="https://investorplace.com/stock-quotes/tdup-stock-quote/">TDUP</a>) shares are falling more than 12% on Wednesday.</li>



<li>ThermoGenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/thmo-stock-quote/">THMO</a>) stock is decreasing over 12% on an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318372198&amp;type=PDF&amp;symbol=THMO&amp;cdn=06c6f2748734640b337b89e0d63957b3&amp;companyName=ThermoGenesis+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-04">updated agreement with CBR Systems</a>.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-5th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Bone Biologics to raise $2.1M through exercise of warrants

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning and more earnings reports, an acquisition deal, liquidation news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Iteris (NASDAQ:<a href="https://investorplace.com/stock-quotes/iti-stock-quote/">ITI</a>) stock is rocketing more than 62% <a href="https://www.nasdaq.com/press-release/iteris-be-acquired-almaviva-335-million-2024-08-09">alongside an acquisition deal</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are soaring over 61% on a <a href="https://www.nasdaq.com/press-release/nauticus-robotics-enters-aquanaut-mark-2-testing-partnership-fau-2024-08-08">new testing partnership</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) stock is surging more than 37% alongside heavy pre-market trading.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are gaining over 30% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318504957&amp;type=PDF&amp;symbol=BBLG&amp;cdn=81b72413280ee9face7494c21cc37055&amp;companyName=Bone+Biologics+Corp&amp;formType=ARS&amp;formDescription=Annual+Report+to+Security+Holders&amp;dateFiled=2024-08-08">release of its annual report</a>.</li>



<li>Pitney Bowes (NYSE:<a href="https://investorplace.com/stock-quotes/pbi-stock-quote/">PBI</a>) stock is rising more than 30% on plans to <a href="https://finance.yahoo.com/news/pitney-bowes-liquidate-ecommerce-unit-221312483.html">liquidate its e-commerce unit</a>.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) shares are increasing over 28% after <a href="https://www.businesswire.com/news/home/20240808458407/en/Marin-Software-Extends-Reach-with-Reddit-and-X-Support">adding support for Reddit and X</a>, previously called Twitter.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) stock is heading more than 27% higher without any clear news this morning.</li>



<li>Doximity (NYSE:<a href="https://investorplace.com/stock-quotes/docs-stock-quote/">DOCS</a>) shares are climbing over 27% on a <a href="https://www.marketwatch.com/story/doximity-shares-rally-after-beating-1q-earnings-guidance-expectations-b9ce97d7?mod=markets">fiscal Q1 earnings beat</a>.</li>



<li>Satellogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/satl-stock-quote/">SATL</a>) stock is jumping more than 26% today.</li>



<li>Babcock &amp; Wilcox (NYSE:<a href="https://investorplace.com/stock-quotes/bw-stock-quote/">BW</a>) shares are up over 25% after releasing its <a href="https://www.businesswire.com/news/home/20240808728017/en/Babcock-Wilcox-Enterprises-Reports-Second-Quarter-2024-Results-Earnings-Growth-Driven-By-Strong-Operating-Performance">Q2 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>AN2 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/antx-stock-quote/">ANTX</a>) stock is diving more than 33% <a href="https://www.nasdaq.com/press-release/an2-therapeutics-provides-update-ebo-301-phase-2-3-study-evaluating-epetraborole">with a clinical trial update</a>.</li>



<li>American Vanguard (NYSE:<a href="https://investorplace.com/stock-quotes/avd-stock-quote/">AVD</a>) shares are tumbling over 29% with the <a href="https://www.nasdaq.com/press-release/american-vanguard-reports-q2-2024-results-2024-08-08">release of its latest earnings report</a>.</li>



<li>PubMatic (NASDAQ:<a href="https://investorplace.com/stock-quotes/pubm-stock-quote/">PUBM</a>) stock is taking a more than 27% beating on <a href="https://www.stocktitan.net/news/PUBM/pub-matic-announces-second-quarter-2024-financial-zmrbbq0dmfh8.html">missed Q2 revenue</a>.</li>



<li>Eventbrite (NYSE:<a href="https://investorplace.com/stock-quotes/eb-stock-quote/">EB</a>) shares are sliding over 23% alongside <a href="https://www.tipranks.com/news/company-announcements/eventbrite-announces-layoffs-and-welcomes-new-coo-cfo">layoffs and leadership changes</a>.</li>



<li>Beauty Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/skin-stock-quote/">SKIN</a>) stock is decreasing more than 22% after <a href="https://www.nasdaq.com/press-release/beautyhealth-reports-second-quarter-2024-financial-results-2024-08-08">posting its Q2 earnings report</a>.</li>



<li>Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) shares are dropping over 21% with its <a href="https://www.nasdaq.com/press-release/cuterar-announces-second-quarter-2024-financial-results-2024-08-08">latest earnings news</a>.</li>



<li>Microvast (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>) stock is falling more than 19% after releasing its <a href="https://ir.microvast.com/static-files/b376f438-a4e5-4a1a-ac22-a6107e450b24">Q2 2024 earnings</a>.</li>



<li>FiscalNote (NYSE:<a href="https://investorplace.com/stock-quotes/note-stock-quote/">NOTE</a>) shares are slipping over 18% after <a href="https://finance.yahoo.com/news/fiscalnote-holdings-inc-note-reports-231505554.html">posting a Q2 loss</a>.</li>



<li>Nerdy (NYSE:<a href="https://investorplace.com/stock-quotes/nrdy-stock-quote/">NRDY</a>) stock is dipping more than 18% after <a href="https://www.nasdaq.com/press-release/nerdy-announces-second-quarter-2024-financial-results-2024-08-08">releasing its Q2 earnings report</a>.</li>



<li>Five9 (NASDAQ:<a href="https://investorplace.com/stock-quotes/fivn-stock-quote/">FIVN</a>) shares close out our pre-market stock movers down over 15% with its <a href="https://www.nasdaq.com/press-release/five9-surpasses-1-billion-annual-revenue-run-rate-2024-08-08">most recent earnings report</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the second quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -67 cents. This was above the analyst estimate for EPS of -$1.39.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bblg-stock-earnings-bone-biologics-for-q2-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024

ALLR

ANTX

ARQT

ASNS

ATCH

ATIP

ATPC

AZTR

BBLG

CAPR

CJET

CLDI

CMND

CONN

CUTR

DOCS

DRMA

FIVN

FRES

GDHG

HOTH

HSCS

HUGE

KITT

LSDI

MITQ

MLGO

MRIN

MVST

NDRA

NEPH

NIVF

NOTE

NRDY

NTBL

NUZE

NVAX

PIRS

PMNT

PUBM

SAGE

SATL

SFIX

SKIN

SLRX

SOAR

SOBR

SSNT

TDUP

THMO

UCAR

VSTE

VSTM

VTAK

WKME

YGMZ

Press Releases

Bone Biologics Reports Progress With NB1 Clinical Program

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Executives to be Interviewed in a "CEO Chat" by Zacks Small-Cap Research Analyst on June 20th

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Bone Biologics

Interés en corto

Bone Biologics (NASDAQ:BBLG) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL